12.07.2015 Views

The Clinical Guide to Supportive and Palliative Care for HIV/AIDS

The Clinical Guide to Supportive and Palliative Care for HIV/AIDS

The Clinical Guide to Supportive and Palliative Care for HIV/AIDS

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

A <strong>Clinical</strong> <strong>Guide</strong> <strong>to</strong> <strong>Supportive</strong> <strong>and</strong> <strong>Palliative</strong> <strong>Care</strong> <strong>for</strong> <strong>HIV</strong>/<strong>AIDS</strong> • Chapter 27: Pharmacologic Interactions of <strong>Clinical</strong> SignificanceMeasures <strong>to</strong> increase gastric acidity <strong>for</strong> azole bioavailability: Administration of acidic beveragessuch as 240 ml of orange juice, <strong>to</strong>ma<strong>to</strong> juice, ginger ale, grapefruit juice or cola drinks in thepresence of achlorhydria of advanced <strong>HIV</strong> disease will enhance azole biovailability, especially<strong>for</strong> ke<strong>to</strong>conazole. When hypochlorhydria is severe, each 200 mg of ke<strong>to</strong>conazole should be dissolvedin 4 ml of 0.2N hydrochloric acid. A straw should be used <strong>to</strong> avoid contact with teeth.PIs <strong>and</strong> NNRTIs with azoles: As a general rule, use of ke<strong>to</strong>conazole with PIs <strong>and</strong> NNRTIs is notadvised due <strong>to</strong> a large number of potentially significant drug-drug interactions. Fluconazole(Diflucan) is preferred. (See Tables 27-2 <strong>and</strong> 27-3.)• Indinavir:Levels are increased 68%; reduce indinavir dose <strong>to</strong> 600 mg q 8 h; SQV levels increasedthree-fold, no dose change required.• Ri<strong>to</strong>navir:Levels are increased more than three-fold; use less than 200 mg ke<strong>to</strong>conazole/day.• Amprenavir:Levels are increased 31% <strong>and</strong> ke<strong>to</strong>conazole levels increased 44%; dose implications notclear.• Nelfinavir:No dosage change.• Nevirapine:Levels are increased 15% <strong>to</strong> 30% <strong>and</strong> ke<strong>to</strong>conazole levels decreased by 60%; combinationis not recommended.• Efavirenz:Interactions between ke<strong>to</strong>conazole <strong>and</strong> efavirenz have not been studied; no recommendationscan be made at present.Ke<strong>to</strong>conazole <strong>and</strong> other drugs: Rifampin decreases activity of both drugs; INH decreases effec<strong>to</strong>f ke<strong>to</strong>conazole; terfenadine <strong>and</strong> cisapride (both now removed from the market) lead <strong>to</strong> ventriculararrhythmias <strong>and</strong> concurrent use should be avoided.Didanosine: Didanosine buffered <strong>for</strong>mulations usually cause problems of absorption <strong>for</strong> medicationswhose absorption are pH-sensitive. Didanosine can decrease absorption of itraconazole,ke<strong>to</strong>conazole, dapsone <strong>and</strong> delavirdine (Rescrip<strong>to</strong>r) because of increased gastric pH. It can alsodecrease absorption of the quinolones <strong>and</strong> tetracyclines by chelation of these antibiotics withthe calcium <strong>and</strong> magnesium ions contained in the buffer.Oral fluoroquinolones: With oral fluoroquinolones, patients should avoid dairy products, elementalminerals <strong>and</strong> heavy nutritional supplements; take fluoroquinolones two hours be<strong>for</strong>e orsix hours after these items.554U.S. Department of Health <strong>and</strong> Human Services • Health Resources <strong>and</strong> Services Administration • <strong>HIV</strong>/<strong>AIDS</strong> Bureau

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!